NPS Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. shook hands on a merger that would create a combined company valued at $1.6 billion, a deal in which NPS essentially is offering about $750 million in stock for Enzon. (BioWorld Today) Read More